GT Biopharma Inc.

17.85-0.1500-0.83%Vol 607.42K1Y Perf 438.07%
Jun 14th, 2021 16:00 DELAYED
BID17.85 ASK17.94
Open18.05 Previous Close18.00
Pre-Market- After-Market-
 - -  - -%
Target Price
23.67 
Analyst Rating
— — 0.00
Potential %
32.61 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap377.13M 
Earnings Rating
Price Range Ratio 52W %
89.37 
Earnings Date
21st May 2021

Today's Price Range

17.6019.73

52W Range

2.0419.73

5 Year PE Ratio Range

-0.10000.2000

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-0.67%
1 Month
44.89%
3 Months
194.07%
6 Months
238.71%
1 Year
438.07%
3 Years
-45.88%
5 Years
-98.97%
10 Years
-99.98%

TickerPriceChg.Chg.%
GTBP17.85-0.1500-0.83
AAPL130.483.13002.46
GOOG2 527.0413.11000.52
MSFT259.892.00000.78
XOM62.07-0.1000-0.16
WFC45.15-0.5300-1.16
JNJ165.370.41000.25
FB336.775.51001.66
GE13.47-0.2200-1.61
JPM157.57-2.7200-1.70
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.25-1.83-632.00
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.25
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume607.42K
Shares Outstanding21.13M
Trades Count4.47K
Dollar Volume2.08M
Avg. Volume481.37K
Avg. Weekly Volume288.05K
Avg. Monthly Volume371.17K
Avg. Quarterly Volume580.12K

GT Biopharma Inc. (NASDAQ: GTBP) stock closed at 17.85 per share at the end of the most recent trading day (a -0.83% change compared to the prior day closing price) with a volume of 607.46K shares and market capitalization of 377.13M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 2 people. GT Biopharma Inc. CEO is Anthony J. Cataldo.

The one-year performance of GT Biopharma Inc. stock is 438.07%, while year-to-date (YTD) performance is 147.64%. GTBP stock has a five-year performance of -98.97%. Its 52-week range is between 2.04 and 19.73, which gives GTBP stock a 52-week price range ratio of 89.37%

GT Biopharma Inc. currently has a PE ratio of -2.30, a price-to-book (PB) ratio of 15.72, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -2 066.58%, a ROC of -% and a ROE of 60.39%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from GT Biopharma Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.25 for the next earnings report. GT Biopharma Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for GT Biopharma Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for GT Biopharma Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

GT Biopharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

GT Biopharma Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 41.37, ATR14 : 1.31, CCI20 : 72.56, Chaikin Money Flow : 0.28, MACD : 1.47, Money Flow Index : 78.98, ROC : 16.88, RSI : 62.59, STOCH (14,3) : 77.88, STOCH RSI : 0.53, UO : 48.91, Williams %R : -22.12), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of GT Biopharma Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

GT Biopharma Inc.

GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

CEO: Anthony J. Cataldo

Telephone: +1 800 304-9888

Address: 9350 Wilshire Boulevard, Beverly Hills 90212, CA, US

Number of employees: 2

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

News

Stocktwits